Home Efficacy & Safety Chronic kidney disease
Illustrative background image
Chronic kidney disease

Chronic kidney disease

Anemia due to chronic kidney disease (CKD)1

PROCRIT® is indicated for the treatment of anemia due to CKD, including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.

PROCRIT® has not been shown to improve quality of life, fatigue, or patient well-being.

PROCRIT® is not indicated for use:

When treating anemia in CKD patients not on dialysis

Selected safety profile1

WARNINGS: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE

Chronic Kidney Disease:

Expand the Important Safety Information at the bottom of the page to see the complete Boxed Warnings.

The adverse reactions with a reported incidence of ≥5% in PROCRIT®-treated patients and that occurred at a ≥1% higher frequency than in placebo-treated patients are shown in the table below:

Adverse reactions in patients with CKD not on dialysis1

ADVERSE REACTION PROCRIT®-treated patients (n=131) Placebo-treated patients (n=79)
Hypertension 13.7% 10.1%
Arthralgia 12.2% 7.6%

Reference

  1. PROCRIT® (epoetin alfa) Prescribing Information. Janssen Products, LP.
EXPAND